New Delhi: Sun Pharmaceuticals stocks are doing well, trading 0.70% up at Rs 817.50, having just received approval for a new drug from the US Food and Drug Administration (USFDA), with Bharti Airtel also doing well, trading 3.19% up at Rs 344.95.
Sun Parmaceuticals’ new drug, BromSite, is to be used for treating inflammation and prevent pain during cataract surgery. It has just received approval from the USFDA.
Bharti Airtel’s subsidiary Bharti Hexaco have just entered into an agreement with Aircel and its subsidiaries to acquire rights to use 20 MHz of 2300 band 4G spectrum for eight circles for an aggregate consideration of Rs 3,500 crore.
Also to be noted, Rupa & Company stocks, which are trading 20% up at Rs. 329.40 having acquired the exclusive license from French Connection to manufacture FCUK products in India, and DLF stocks which are soon to sell off 40% of the promoters’ stake in its rental arm for a deal of Rs 12,000-14,000 crore.